UK – GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia
The agency’s final draft guidance applies to both newly diagnosed and previously treated patients, although those eligible will need to have either not been...
Europe – Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 September 2023
New safety information for Omega-3-acid ethyl esters
The PRAC agreed to add atrial fibrillation (irregular, rapid contraction of the heart) as a common side effect to the product...
